by Madaline Spencer | Jan 20, 2026
Catherine M. Broome, MD, Professor of Medicine and Director of Cellular Apheresis, Lombardi Cancer Center, MedStar Georgetown University, discusses real world safety data of Enjaymo (sutimlimab) in patients with cold agglutinin disease (CAD). CAD is a...
by Madaline Spencer | Jan 19, 2026
David Kuter, MD, DPhil, Professor of Medicine at Harvard Medical School, Massachusetts General Hospital, discusses treatment with rilzabrutinib in patients with immune thrombocytopenia (ITP). ITP is an autoimmune bleeding disorder characterized by too few...
by Madaline Spencer | Jan 16, 2026
Anita Hill, MD, PhD, Global Medical Head for Hematology & Nephrology and Transplant at Alexion, AstraZeneca Rare Disease, discusses recent data on ravulizumab in rare hematologic conditions. Thrombotic Microangiopathies Following Hematopoietic Stem Cell...
by Madaline Spencer | Jan 15, 2026
A recent paper published in Molecular Genetics and Metabolism presented safety and efficacy outcomes from the 48-month open-label extension of the NPC-002 study of arimoclomol in patients with Niemann-Pick type C (NPC). NPC is a complex lipid storage disease caused by...
by Madaline Spencer | Jan 14, 2026
Jan Klatt, MD, Head of Development Unit Neurology & Immunology, Merck Healthcare, Germany, discusses the U.S. Food and Drug Administration’s (FDA) Fast Track designation of cladribine capsules for patients with generalized myasthenia gravis (gMG). ...
